Genoscience Pharma is a French private biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in a global clinical trial. Our business models relies on the approval of Breakthrough Therapy Designation, meaning that we are committed to resolve unmet needs in Oncology.
Our Financial Structure
2018
Most Innovative SME
10-50
Employees
2
Financing Rounds
20
Total Investment
We are a private company with a supportive shareholder base, among whom world-renowned business angels, with successful experience in managing innovation in pharmaceutical industry.
We have also received grants and refundable advances from French institutions including BPIFrance and PACA region.
In addition, our innovative project was rewarded several times.
- 9th edition of the ‘Most Innovative European Biotech SME Award’ in Healthcare category with EuropaBio
- ‘Advance Biotech Grant Program‘ in Europe from Merck
- SME Seal of Excellence from the European Commission
- ‘Programme d’Investissements d’Avenirs (PIA)’ in France from the PSPC-COVID call operated on behalf of The French Government by Bpifrance
GENOSCIENCE PHARMA
SIÈGE SOCIAL
10 RUE D’IÉNA
13006 MARSEILLE
FRANCE
Phone : +33 (0) 4 91 26 99 50
Fax : +33(0) 4 91 26 99 51
investors@genosciencepharma.com
